ArticleThe oncologist2026

BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions.

Samer Al Hadidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.